<DOC>
	<DOCNO>NCT02226198</DOCNO>
	<brief_summary>The purpose study establish efficacy , safety tolerability rosuvastatin child adolescents homozygous familial hypercholesterolemia .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Rosuvastatin Children Adolescents With Homozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-center , cross-over study efficacy , safety tolerability rosuvastatin child adolescent ( age 6 &lt; 18 year ) homozygous familial hypercholesterolemia ( HoFH ) . The study design assess efficacy rosuvastatin 20 mg compare placebo lipid , lipoproteins apolipoproteins pediatric patient HoFH . The outcome measure assess include low density lipoprotein cholesterol ( LDL-C ) , high density lipoprotein cholesterol ( HDL-C ) , total cholesterol ( TC ) , triglyceride , non-HDL-C , LDL-C/HDL-C , TC/HDL-C , non-HDL-C/HDL-C , apolipoprotein B ( ApoB ) , apolipoprotein A 1 ( ApoA-1 ) ApoB/ApoA-1 follow 6 week treatment rosuvastatin 20 mg placebo . Pharmacokinetic data trough plasma exposure rosuvastatin also assess pediatric patient HoFH .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Prior study relate procedure perform , provision write informed consent parent/both parent guardian statement assent child adolescent ( require Institutional Review Board [ IRB ] Independent Ethics Committee [ EC ] accord local regulation guideline ) . Communication Investigator , patient/guardian child/adolescent confirm understanding require compliance requirement study . 2 . Male female child adolescent ( age 6 &lt; 18 year ) least 1 follow criterion : Documentation genetic test confirm 2 mutated allele LDL receptor gene locus ; and/or Documented untreated LDL C &gt; 500 mg/dL ( 12.9 mmol/L ) triglyceride ( TG ) &lt; 300 mg/dL ( 3.4 mmol/L ) least 1 follow criterion : 1 . Tendinous and/or cutaneous xanthoma prior 10 year age ; 2 . Documentation HoFH parent : genetic and/or clinical criterion 3 . Negative pregnancy test ( b human chorionic gonadotropin analysis ) prior baseline female child bear potential : Female patient child bear potential must adhere pregnancy prevention method ( abstinence , chemical , mechanical ) study 3 month follow last dose . Male patient refrain father child ( include sperm donation ) study 3 month follow last dose ; 4 . Willing follow study procedure include adherence dietary guideline , study visit , fast blood draw , compliance study treatment regimen . Exclusion Criteria 1 . History statin induct myopathy serious hypersensitivity reaction HMG CoA reductase inhibitor ( statin ) , include rosuvastatin , Visit 1 . 2 . Fasting serum glucose &gt; 9.99 mmol/L ( 180 mg/dL ) glycosylated hemoglobin &gt; 9 % Visit 1 patient history diabetic ketoacidosis within past year . 3 . Uncontrolled hypothyroidism define thyroid stimulate hormone ( TSH ) &gt; 1.5 time upper limit normal ( ULN ) Visit 1 patient whose thyroid replacement therapy initiate modify within last 3 month prior Visit 2 . 4 . Current active liver disease hepatic dysfunction ( except confirm diagnosis Gilbert 's disease ) define elevation 1.5 time upper limit normal ( ULN ) age follow liver function test Visit 1 : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) , bilirubin . 5 . Definite suspect personal history family history clinically significant adverse drug reaction ( ADRs ) , hypersensitivity drug similar chemical structure rosuvastatin well statins .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>LDL-C</keyword>
	<keyword>HoFH</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>